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ABSTRACT
Studies of lysozyme have played a major role over several decades
in defining the general principles underlying protein structure,
folding, and stability. Following the discovery some 10 years ago
that two mutational variants of lysozyme are associated with
systemic amyloidosis, these studies have been extended to inves-
tigate the mechanism of amyloid fibril formation. This Account
describes our present knowledge of lysozyme folding and misfold-
ing, and how the latter can give rise to amyloid disease. It also
discusses the significance of these studies for our general under-
standing of normal and aberrant protein folding in the context of
human health and disease.
1. Introduction
Since its discovery by Alexander Fleming in 1922, human
lysozyme has been a rich source of information on many
fundamental aspects of protein science. Moreover, in the
early 1990s, it was found that two lysozyme variants (I56T
and D67H) are associated with a form of hereditary
nonneuropathic systemic amyloidosis in which amyloid
fibrils containing the full-length variant proteins are
deposited in various organs1 [Figure 1]. More recently,
other naturally occurring amyloidogenic variants (F57I,
F57I/T70N, W64R, and T70N/W112R)2-4 and one non-
amyloidogenic variant (T70N)5 have been reported. The
depth of knowledge that has accumulated on wild-type
lysozyme (for reviews see refs 6 and 7) has enabled
detailed studies of the effects of these mutations on the
properties of the protein including its folding, stability,
and aggregation behavior. In this Account, we summarize
the results of these studies and describe how they provide
molecular insights into both the mechanism by which
lysozyme converts in vitro into its fibrillar state and the
origin of the amyloid disorder with which this process is
associated in vivo. In addition, we discuss the significance
of the study of lysozyme for understanding the more
general issues of protein misfolding and the nature of
protein deposition diseases. Finally, we show how the
results of these studies give rise to new insights into the
structures of proteins and the evolutionary pressures that
have resulted in their remarkable and varied character-
istics.
2. Folding and Unfolding of Human Lysozyme
Wild-type human lysozyme is a 14 kDa enzyme, whose
native structure consists of two closely interacting struc-
tural regions called the R-domain and the â-domain, and
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FIGURE 1. Posterior whole-body scintigraphic images following
intravenous injection of 123I-human serum amyloid protein that binds
selectively to amyloid deposits: (A) from a patient with lysozyme
amyloidosis showing heavy amyloid deposition in the liver, spleen,
and kidneys; (B) from a normal subject showing the absence of
protein deposits and distribution of the tracer throughout the blood
pool. Adapted from ref 35.
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is cross-linked by four disulfide bonds, one of which (77-
95) links the two domains [Figure 2]. All natural mutations
discovered so far are located in the â-domain with the
exception of the W112R mutation, which is in the D helix
of the R-domain [Figure 2]; this latter mutation has,
however, only been found in conjunction with the â-do-
main mutation T70N. X-ray crystallographic data have
shown that the I56T, D67H, and T70N variants have the
same overall native fold as the wild-type protein with all
disulfide bonds correctly formed.8,9 These variants are
functional, with specific activities very similar to that of
the wild-type protein.8,10
Folding from the Reduced State. Because lysozyme is
an extracellular protein, its folding in vivo takes place in
the oxidizing environment of the lumen of the endoplas-
mic reticulum prior to secretion via the Golgi apparatus.
The refolding of the wild-type, I56T, and D67H lysozymes
from their reduced states in guanidinium chloride (where
the protein is highly denatured and with all eight cysteine
residues in the free thiol form) has therefore been studied
in vitro under oxidative conditions designed to mimic, at
least in general terms, protein folding in the endoplasmic
reticulum.11
Under these conditions, the reduced proteins all cor-
respond to ensembles of unfolded conformers, and in the
initial stages of folding these species collapse rapidly via
a large number of parallel pathways to form a multitude
of relatively unstructured intermediates having one or two
disulfide bonds. The majority of these species then fold
to form a native-like three-disulfide intermediate lacking
the (77-95) bond. The final and slowest step involves a
conformational rearrangement requiring at least local
unfolding of these latter species in order to allow the
remaining free thiol groups to form the fourth disulfide
linkage and hence to generate the fully oxidized native
protein. Although, the I56T and D67H variants refold in a
manner qualitatively similar to that of wild-type lysozyme,
an interesting and initially unexpected finding is that they
fold faster by a factor of 2 and 3, respectively.11 The origin
of this observation, however, can be attributed primarily
to the fact that the lower stabilities of the native-like
intermediates of the variants compared with those of the
wild-type protein facilitate the conformational rearrange-
ments associated with the final folding step.
Folding in the Presence of Disulfide Bonds. The
efficient in vitro oxidative folding of the variant proteins
is consistent with the finding that ex vivo lysozyme fibrils
are composed only of full-length variant proteins contain-
ing all native disulfide bonds.1,8 Moreover, because these
pathological fibrillar deposits are predominantly extra-
cellular, it is likely that the amyloidogenic variants are not
only synthesized but also secreted correctly in significant
quantities; the folding and unfolding processes underlying
their later conversion into amyloid fibrils will therefore
in all probability involve only species in which all four
disulfide bonds are correctly formed. We and others have
studied these processes in vitro in detail for wild-type
lysozyme and some of its natural variants. These studies
have been described extensively in previous review ar-
ticles,6,7 and we shall therefore simply summarize here the
most important findings.
The unfolding kinetics of the I56T, D67H, and T70N
variants and wild-type lysozyme in high concentrations
of guanidinium chloride have all been found to fit well to
single-exponential functions. However, the T70N, I56T,
and D67H variants unfold, respectively, about 3, 30, and
160 times faster than wild-type lysozyme.10,12 The refolding
of wild-type lysozyme from its guanidinium chloride
denatured state occurs via multiple parallel tracks and
through a series of well-defined metastable intermediates
that become progressively structured in discrete domains.
The majority of the protein molecules follow a slow track,
the first step of which involves the stabilization of the A
and B helices and the C-terminal 310 helix in a locally
cooperative manner.12,13 This step is followed by the
cooperative folding of helices C and D leading to an
intermediate in which the R-domain has a native-like
structure and then by the folding of the â-domain. As
found for the homologous hen egg-white lysozyme, it is
likely that a final step involving the docking of the two
domains is required to generate the native close-packed
structure with a functional active site.6,7 About 10% of the
FIGURE 2. Ribbon diagram of the structure of human wild-type
lysozyme showing the locations of the known natural mutations,
along with the year of their discovery. The six mutations give rise to
seven amyloidogenic variants shown in blue and one nonamy-
loidogenic variant shown in black. The single point mutant W112R
has not yet been detected. The four R-helices in the R-domain are
labeled A through D. The four disulfide bonds are shown in red.
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molecules, however, fold along a fast track in which the
native state is formed more efficiently than it is for the
majority of molecules, because the â-domain becomes
structured concomitantly with the R-domain. These ob-
servations are similar to those obtained for the folding of
hen lysozyme and the homologous R-lactalbumins [Figure
3]. All of these studies have contributed to the develop-
ment of a “new view” of protein folding in terms of a
stochastic search process on a highly evolved energy
landscape determined by the protein sequence14,15 [Figure
3].
The refolding of both the I56T and D67H variants also
occurs via multiple parallel pathways and through a series
of well-defined intermediates. The refolding of the D67H
variant is virtually identical to that of the wild-type protein,
whereas for the I56T variant, the coalescence of the
â-domain onto the folded R-domain is about 10 times
slower.12 These findings can be attributed to the fact that
residue 67 is located in a loop region within the â-domain,
while residue 56 is located at the crucial interface between
the R and â domains.
3. Misfolding and Aggregation of Human
Lysozyme
Reduced Stability and Cooperativity of the Amyloidogen-
ic Variants. The thermostability of all four single-point
amyloidogenic variants (I56T, F57I, W64R, and D67H) is
remarkably decreased by almost exactly the same amount
(12 ( 2 °C at pH 5.0) relative to the wild-type protein;8,16,17
by contrast, the nonamyloidogenic T70N variant is only
marginally destabilized (by 4 °C).9,10 Moreover, not only
do the amyloidogenic mutations drastically reduce the
stability of the protein, but they also significantly reduce
the cooperativity of the thermal unfolding process.8,16-18
Most importantly, the global cooperativity of the amy-
loidogenic variants is substantially reduced at equilibrium
under physiologically relevant conditions;16,19 hydrogen/
deuterium exchange experiments monitored by mass
spectrometry and NMR spectroscopy have clearly dem-
onstrated that at pH 5-8 and 35-37 °C, both the I56T
and D67H variants populate transiently a partially un-
folded species [Figure 5a]. In this intermediate species,
which is remarkably similar for both variants despite the
different locations of the mutations, the regions of the
protein that form the â-domain and the adjacent C-helix
in the native state are simultaneously unfolded, whereas
the regions forming the remainder of the R-domain
maintain their native-like structure [Figure 5f].16,19
This partial and transient unfolding event is not detect-
able in vitro for the nonamyloidogenic T70N variant or
for the wild-type protein under physiologically relevant
conditions; it is, however, detectable for these two proteins
under more destabilizing conditions.9 Taken together,
these results suggest that T70N lysozyme is not sufficiently
destabilized to allow population of the amyloidogenic
intermediate under physiological conditions at a level that
results in pathogenic aggregation. This conclusion ratio-
nalizes the fact that the T70N mutation has not been
found to form amyloid fibrils in people carrying this
mutation and suggests that there may be only a relatively
narrow window of stability that results in pathogenic
behavior. In accord with this conclusion, although patients
suffering from lysozyme amyloidosis are all heterozygotes,
the deposits appear to be composed exclusively of the
amyloidogenic variants.1,8
To begin to explore further the link between stability
and amyloid disease, we have investigated the levels of
secretion of a range of mutational variants of lysozyme
in Pichia pastoris into which the lysozyme gene has been
inserted.17 In this eukaryotic organism, we have observed
a strong correlation between the thermostability of each
variant and its secretion level, presumably because the
latter reflects a lower probability of satisfying the quality
FIGURE 3. A schematic free-energy (F) surface illustrating the
folding of hen lysozyme. QR and Qâ represent the number of native
contacts present in the R-domain and â-domain, respectively, at
different stages of folding. Protein molecules are initially in a
denatured ensemble and two trajectories are illustrated by which
they can achieve the native fold. One represents a “fast track”
(yellow trajectory) and shows a lysozyme molecule in which native-
like structure in the two domains forms concurrently and the
molecule populates an intermediate state (B) briefly prior to achieving
the native state (C). Another lysozyme molecule is illustrated following
a “slow track” (cyan trajectory) in which the polypeptide chain
becomes temporarily trapped in an intermediate state (A), which
contains persistent structure in the R-domain but not the â-domain;
further folding of this intermediate involves either a transition over
a higher barrier or partial unfolding to enable the remainder of the
folding process to occur along the fast track. The ensembles of
structures shown for the intermediate states (A and B) are based
on restrained molecular dynamics simulations using experimental
data from studies of human R-lactalbumin, a protein homologous
to hen lysozyme and for which stable intermediates can be
generated and studied in detail.36
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control mechanisms within the cell for protein of reduced
stability. As far as amyloid disease is concerned, a lower
level of protein secretion will, at least in the absence of
other factors, reduce the probability of aggregation in the
extracellular environment, but the reduced stability of the
native state will increase the probability of aggregation.
A complex interplay between reduced stability, lower
secretion levels, and intrinsic aggregation propensity is
therefore likely to determine the types of mutation that
give rise to familial forms of amyloid disease.17
Links between Normal Folding and Amyloid Forma-
tion. The I56T, D67H, and T70N variants, and indeed wild-
type human lysozyme, are all able to form amyloid fibrils
in vitro when they are incubated under conditions where
a significant fraction of the protein molecules are at least
partially unfolded, such as low pH, high temperature, or
moderate concentrations of denaturant.6,7 However, as a
result of their lower stability and cooperativity, and
therefore their higher ability to populate partially unfolded
states, the amyloidogenic variants form fibrils in vitro
much more easily than the T70N variant and especially
than the wild-type protein.9,18 Fibrils formed in vitro from
the various lysozyme species studied in this way do,
however, resemble those formed in vivo, and their amyloid
character has been shown by a wide variety of tech-
niques,6,7 some of which are illustrated in Figure 4. The
kinetics of in vitro aggregation are sigmoidal, showing a
lag phase followed by exponential growth [Figure 4a].
Moreover, fibril formation by I56T, D67H, and wild-type
lysozymes are greatly accelerated by seeding with pre-
formed fibrils formed from either a variant or the wild-
type protein.18 These results are all consistent with a
nucleation-dependent growth process that increasingly
appears to be a common feature of fibril formation.6,7
One of the most striking features of the transiently
populated intermediates characterized for the amyloidogen-
ic I56T and D67H variants under physiologically relevant
conditions is that they have marked similarities not just
to each other but also to the dominant R-domain inter-
mediate detected during their nonoxidative folding. This
observation can be rationalized on the basis of structural
data which suggest that, for both variants, mutations
destabilize the interface between the R- and â-domains.
Indeed, perturbation of this region is likely to be the key
factor in the reduction of the cooperativity between the
two domains of the native proteins and of the stability of
the â-domain and the C-helix, which are linked via the
77-95 disulfide bond.8 As a substantial part of the region
destabilized by the mutations forms â-sheet structure in
the native protein, the initial steps in the aggregation
process could simply involve the formation of intermo-
lecular interactions such as hydrogen bonds in the region
of the protein that is transiently exposed in the intermedi-
ate, rather than the intramolecular interactions charac-
teristic of the native structure [Figure 5c]. These obser-
vations suggest that the processes of protein folding and
aggregation are closely coupled and underline the need
to study both processes in detail to understand properly
how they occur and how they are connected to each other.
When the structurally homologous hen lysozyme is
incubated at low pH and elevated temperatures, peptide
fragments corresponding to parts of the â-domain and to
all of the C-helix are readily cleaved from the protein.20
Remarkably, these fragments correspond almost exactly
to the regions of the I56T and D67H human variants that
unfold to form the intermediates discussed above. In
addition, these fragments have been found to form
amyloid fibrils rapidly after purification; by contrast, the
fragments corresponding to the rest of the protein remain
predominantly soluble under the same conditions. This
result indicates that the region of lysozyme corresponding
to the â-domain and the C-helix not only can unfold with
local cooperativity but also has a higher intrinsic propen-
sity to aggregate than other regions of the protein.
Interestingly, a similar result is predicted for human
lysozyme by analyzing its sequence with an algorithm
developed to rationalize the relative aggregation propensi-
ties of different polypeptides.21 The highly amyloidogenic
character of this region is probably the reason all but one
of the known amyloidogenic mutations are localized in
the â-domain. The fact that the single R-domain mutation,
W112R, has only been found in conjunction with the
â-domain mutation T70N4 suggests that this substitution
results in additional destabilization of the T70N variant
enabling it to form pathogenic aggregates in vivo.
Inhibition of Amyloid Formation. The detail in which
the processes of lysozyme folding and amyloid formation
are understood provides an important opportunity to
design strategies to inhibit the conversion of the variants
FIGURE 4. In vitro formation of amyloid fibrils by human lysozyme:
(a) time course of the aggregation of the D67H and wild-type proteins
monitored by light-scattering; (b) representative transmission electron
microscopy image of fibrils formed from the D67H variant; (c) X-ray
fiber diffraction pattern of the same type of fibrils showing a
prominent meridional reflection at 4.7 Å and an equatorial reflection
at 10.4 Å, features typical of the cross-â structure of amyloid fibrils.
Adapted from ref 23.
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into amyloid fibrils. In light of the conclusion that the
lower stability and cooperativity of the amyloidogenic
variants is likely to be a primary factor in their enhanced
amyloidogenicity, we have explored the possibility of
stabilizing these proteins through binding to another
molecule. To test this strategy, we have investigated the
effects of binding a heavy-chain camelid antibody frag-
ment raised against wild-type human lysozyme and
referred to as cAb-HuL6.22 These experiments reveal that
the specific binding of cAb-HuL6 reverses the loss of global
structural cooperativity that results from the mutations;
that is, in the presence of an equimolar quantity of the
antibody fragment virtually none of the molecules of the
I56T and D67H proteins undergoes even a single unfolding
event of the type observed for the lysozyme variants when
unbound. The result of this binding is to prevent the ready
in vitro conversion of the lysozyme variants into their
aggregated states [Figure 5b,d,e].16,23
Structural studies of the complex between wild-type
human lysozyme and cAb-HuL6 have revealed that the
epitope on the lysozyme molecule includes neither the
sites of the mutations nor most of the residues in the
region of the structure that is destabilized by the muta-
tions23 [Figure 5f]. Thus, the effects of binding are not
simply to mask this latter region and prevent its unfolding
from the remainder of the structure. Rather, it appears
that the binding of cAb-HuL6 acts by restoring the global
cooperativity of the native structure via, at least in part,
FIGURE 5. Schematic mechanism of human lysozyme aggregation and of its inhibition by the cAb-HuL6 antibody fragment. Panel a shows
pulse-labeling hydrogen/deuterium exchange experiments analyzed by mass spectrometry. Two peaks are present in the spectra D67H variant,
whereas for wild-type lysozyme under similar conditions a single peak is observed. The additional peak observed for the amyloidogenic
variant (yellow) is attributed to the transient formation of an intermediate in which the â-domain and the C-helix are cooperatively unfolded
but the remainder of the R-domain is native-like (these regions are colored yellow in panel f). In these experiments, the I56T variant has been
found to behave like the D67H variant, whereas the T70N variant behaves like the wild-type protein. Panel c shows the pathway of aggregation
of amyloidogenic lysozyme variants. The formation of intermolecular interactions between molecules in the intermediate state is likely to be
the origin of the aggregation events that ultimately lead to the formation of amyloid fibrils. Note that the native disulfide bridges, though not
represented in this scheme, are present in the fibrils. Panels b and d show stabilization of the lysozyme variants by the antibody fragment.
In the presence of cAb-HuL6 (panel b), the D67H variant appears as a single peak indicating that the binding of cAb-HuL6 inhibits its locally
cooperative unfolding (as shown on Figure 5a). A similar stabilizing effect was observed with the I56T variant. In panel d, the binding of
cAb-HuL6 prevents the ready conversion of the D67H lysozyme into its aggregated state. Again a similar inhibition of aggregation has been
observed with the I56T variant. Panel f shows the X-ray structure of the complex between wild-type lysozyme and cAb-HuL6. Adapted from
ref 37.
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the transmission of small but significant long-range con-
formational effects through the protein to the interface
between the two structural domains. These results dem-
onstrate the close link between the reduction of global
cooperativity in the amyloidogenic variants, and hence
their increased tendency to populate a partially unfolded
intermediate state and their propensity to convert into
amyloid fibrils. These conclusions therefore reinforce the
view that the cooperativity of native protein structures is
an essential evolutionary development to enable otherwise
marginally stable structures to resist aggregation under
conditions in which they exert their biological function.24
4. Relationship to Other Protein Aggregation
Diseases
Generic Aspects of Amyloid Formation and Disease. A
chance observation, made just as we had started to
explore the mechanism of lysozyme fibril formation,
suggested that perfectly ordinary proteins, unrelated to
any known disease, can form amyloid fibrils with all the
characteristics of those found in lysozyme amyloidosis,
or indeed in the 20 or so other related misfolding condi-
tions including Alzheimer’s disease and type II diabetes.25
This finding, which was closely followed by an indepen-
dent report of a similar observation,26 stimulated us to
begin a series of investigations of the abilities of a range
of peptides and proteins to form amyloid fibrils, of the
mechanisms by which they do so, and of the properties
of the aggregates. These studies led us to the conclusion
that many, perhaps in principle nearly all, proteins have
the intrinsic ability to convert into amyloid or amyloid-
like fibrils in vitro if appropriate conditions can be
found.24,27 Further studies also led to the suggestion that
there are likely to be many common structural and
mechanistic features underlying protein misfolding and
aggregation.27 This conclusion is consistent with the fact
that the fibrillar aggregates associated with all the known
amyloid-related diseases appear similar in their overall
character and morphology despite little, if any, similarities
in the sequences or native structures of the peptides or
proteins (whether intact or fragmented) that represent the
major components of the pathological deposits.27
On the basis of this and other such evidence, we believe
that the formation of amyloid fibrils is a consequence of
the inherent physicochemical properties of polypeptide
chains and that amyloid disorders result fundamentally
from the reversion of a peptide or protein in its native
state to this alternative and generic form of polypeptide
structure.24,27,28 In general, as in the case of lysozyme, the
structure of at least some, and perhaps the majority, of
regions of a protein in its fibrillar form will differ sub-
stantially from that of the protein in its functional state,
whether the latter is globular or natively unfolded. In the
case of polypeptides that normally fold to globular struc-
tures, specific packing between the side chains and
exclusion of many of the hydrophobic groups from water
stabilize states in which the main chain is folded into
unique and often highly intricate native structures in
which the surface regions are designed to avoid inap-
propriate intermolecular interactions.29 In these structures,
intramolecular hydrogen bonds are formed between the
main-chain amide and carbonyl groups in the familiar
R-helices, â-sheets, loops, and turns.29 The overall archi-
tecture of a given fold and its net stability relative to that
of other globular folds, the denatured state, or indeed the
amyloid structure, depend on the specific nature of the
side-chain interactions within that fold and so is encoded
in the sequence of the protein. Native proteins, even under
physiological conditions, are at best only marginally stable
relative to these alternatives states.29
While globular proteins in their native states are usually
highly resistant to aggregation because of their close-
packed structures, when such a protein is even partially
or transiently unfolded, its propensity to aggregate can
be dramatically enhanced. In vitro aggregation, including
formation of amyloid fibrils, is therefore often associated
with the disruption of the native structure of a protein
provided the latter occurs under conditions in which
relatively stable noncovalent interactions, particularly
hydrogen bonding, can still occur.24 In vivo, despite the
plethora of housekeeping mechanisms such as molecular
chaperones and the unfolded protein response, there is a
finite chance that any protein molecule produced in a cell
may fail to fold correctly or to remain correctly folded and
hence is prone to aggregate.28 In the case of lysozyme,
our knowledge of the effects of natural amyloidogenic
mutations on the properties of the protein points to the
conclusion that the formation of fibrils in vivo results from
a series of factors that combine to generate pathogenic
behavior. First, the amyloidogenic variants are able to fold
sufficiently well to escape degradation by the cellular
quality control systems and hence to be secreted in
significant amounts into extracellular space where they
normally function. Second, the mutations decrease the
stability and global cooperativity of the protein sufficiently
to enable the variants to unfold partially and populate
intermediate states at a significant level. And third, the
region of the polypeptide chain that is exposed as the
result of this unfolding event is highly aggregation prone
and hence can initiate the events that ultimately lead to
the formation of amyloid fibrils. One can speculate from
these findings that the relative rarity of amyloidoses is
likely to reflect not just the efficiency of the biological
mechanisms that defend against protein aggregation but
also the importance of multiple risk factors of this type
for a given protein.
New Paradigms of Protein Structure. Within the
amyloid core structure, an array of inter- and intramo-
lecular hydrogen bonds is formed between the main-chain
amide and carbonyl groups that are common to all
peptides and proteins (except where proline residues are
present). Both solid-state NMR and X-ray studies suggest
that the side chains of the component amino acid residues
can possess a very high degree of order, akin to the
situation when peptides and other molecules form three-
dimensional crystals.30,31 The interactions between side
chains (and sometimes simply their burial from solvent
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water) will undoubtedly contribute to the stability of the
amyloid structure and explains, at least in part, the fact
that the propensity to convert to this state varies dramati-
cally with the composition and sequence of any given
polypeptide chain.21 In addition, the repetitive nature and
degree of order of the long-range interactions within the
highly organized fibril core are important in stabilizing
the amyloid state.
Fibrils formed from wild-type human lysozyme can
seed the formation of fibrils from solutions of hen
lysozyme, a protein with approximately 60% sequence
identity.32 The efficiency of seeding, however, is lower than
that carried out with preformed fibrils from proteins
having a higher sequence similarity to hen lysozyme
including turkey lysozyme or a single-point mutational
variant of hen lysozyme.32 These results show clearly that
the side chains of the residues involved in the core of the
fibrils, and perhaps also those of the residues that make
up the regions peripheral to the fibril core, influence the
propensity to form the amyloid structure relative to the
many alternative states accessible in principle to a polypep-
tide chain. Side-chain residues have also been shown to
affect the specific details of the fibril structures, for
example, the separation between â-sheets and the manner
in which protofilaments assemble to form fibrils.33 How-
ever, by contrast to the situation for native states, where
the specific interactions of particular side chains is es-
sential to stabilize the overall fold, we believe that in the
amyloid form of a peptide or protein, the side chains,
whatever their nature, generally accommodate themselves
as favorably as possible in a structure whose essential
character is determined by common features of the
polypeptide chain.24
5. Future Perspectives
The diseases associated with protein misfolding are rapidly
emerging as among the most feared and debilitating in
the modern world. We believe that the rapidly increasing
prevalence of disorders such as Alzheimer’s disease and
type II diabetes results ultimately from the fact that our
proteins and the environments in which they function
have been selected by evolution to be resistant to ag-
gregation only to the extent necessary for the competitive
success of our species.24,27 Under other conditions, the
most vulnerable of our proteins will progressively tend to
revert to the generic amyloid structure. In today’s society,
we strive to go beyond our evolutionary fitness through,
for example, extended life spans and radically altered
lifestyles.34 Nevertheless, we believe that studies of the type
described here have begun to generate a sufficiently
profound understanding of the distinctive differences
between normal and aberrant folding behavior and,
hence, identified a wide variety of novel strategies through
which rational therapeutic intervention could lead to
effective prevention or treatment of perhaps the entire
family of protein misfolding disorders28 [Figure 6].
We are grateful to the many students, research fellows, and
colleagues who have worked with us on the topics discussed here.
Much of this Account is based on research that has been carried
out with the generous support of the Leverhulme Trust and the
Wellcome Trust.
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FIGURE 6. Schematic representation of in vivo amyloid fibril formation by lysozyme. After synthesis on the ribosome, the protein folds in the
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